

AGGREGATION OF THERAPEUTIC PROTEINS

Edited by

Wei Wang

Christopher J. Roberts

 **WILEY**

A John Wiley & Sons, Inc., Publication

CONTENTS

| | |
|--|-------------|
| Preface | xvii |
| Contributors | xxi |
| 1. Fundamental Structures and Behaviors of Proteins | 1 |
| <i>Jennifer S. Laurence and C. Russell Middaugh</i> | |
| 1.1 The Problem of Protein Aggregation | 1 |
| 1.1.1 Structural Features of Proteins | 4 |
| 1.1.2 Structural Features of Protein Aggregates | 5 |
| 1.2 Parallels to Protein Folding | 11 |
| 1.3 Views of Protein Stability and Aggregation | 12 |
| 1.3.1 Physicochemical Properties of Proteins | 12 |
| 1.3.2 Surface Properties and Packing Arrangements | 18 |
| 1.3.3 Solvent Interactions | 21 |
| 1.4 Models of Aggregation | 22 |
| 1.4.1 Monomer Conversion | 23 |
| 1.4.2 Oligomeric Intermediates | 24 |
| 1.4.3 Nucleation in Protein Folding | 25 |
| 1.4.4 Domain Swapping | 26 |
| 1.5 Models of Protein Folding | 29 |
| 1.5.1 Classical Models Based on Chemical Equilibrium | 29 |
| 1.5.2 Statistical Mechanical Models | 31 |
| 1.5.3 Computational Models | 33 |
| 1.5.4 Application of Coarse-Grained Models | 35 |
| 1.5.5 Information Theory (IT) | 37 |
| 1.6 Influences of Chemical Alteration on Aggregation | 40 |
| 1.6.1 Length of the Polypeptide Chain | 41 |
| 1.6.2 Methionine Oxidation | 41 |
| 1.6.3 Covalent Cross-Linking of Strands | 42 |
| | vii |

| | | |
|-----------|---|------------|
| 1.6.4 | Deamidation | 44 |
| 1.6.5 | Proline Isomerization | 45 |
| 1.7 | Approaches to Predicting Aggregation | 46 |
| 1.8 | Conclusions | 49 |
| | References | 50 |
| 2. | Protein Aggregation Pathways, Kinetics, and Thermodynamics | 63 |
| | <i>Yi Li and Christopher J. Roberts</i> | |
| 2.1 | Introduction | 63 |
| 2.2 | Native and Nonnative Aggregation Pathways | 66 |
| 2.3 | Thermodynamics of Reversible Self-Association | 69 |
| 2.3.1 | Self-Association of Folded/Native Proteins | 70 |
| 2.3.2 | Nonnative Self-Association | 73 |
| 2.4 | Aggregation Kinetics and Distinguishing Kinetic Pathways | 75 |
| 2.4.1 | Aggregation Kinetics | 75 |
| 2.4.2 | Distinguishing Aggregation Pathways and Rate-Limiting Steps | 78 |
| 2.4.3 | Influence of Adsorption to Macroscopic Surfaces | 80 |
| 2.5 | Chemical Modifications | 80 |
| 2.6 | Effects of Cosolvents or Cosolutes | 82 |
| 2.6.1 | Transfer Free Energies and Preferential Interaction Parameters | 82 |
| 2.6.2 | Relating $\Gamma_{32}^{(\mu_3)}$ to Molecular Interactions | 85 |
| 2.6.3 | An Additive Approach to $\Delta\mu_2^r$, $\partial\mu_2^r/\partial m_3$, and $\Gamma_{32}^{(\mu_3)}$ | 89 |
| 2.6.4 | Predicting Cosolvent/Cosolute Effects on Unfolding, Association, and Aggregation | 93 |
| | Appendix—Derivation of Γ_{32} for van der Waals (vdW) Mixture | 94 |
| | Acknowledgments | 97 |
| | References | 97 |
| 3. | Identification and Impact of Aggregation-Prone Regions in Proteins and Therapeutic Monoclonal Antibodies | 103 |
| | <i>Sandeep Kumar, Xiaoling Wang, and Satish K. Singh</i> | |
| 3.1 | Introduction | 103 |
| 3.2 | Energy Landscapes, Protein Folding, and Aggregation | 105 |
| 3.3 | Prediction of APRs in Proteins and Biotherapeutics | 106 |

| | | |
|-----------|--|------------|
| 3.3.1 | Computational Tools | 106 |
| 3.3.2 | Experimentally Studied Aggregation-Prone Sequences and Sequence Patterns | 109 |
| 3.3.3 | Prediction of APRs in Therapeutic mAbs | 110 |
| 3.3.4 | Other Useful Studies | 113 |
| 3.4 | Conclusions and Future Directions | 114 |
| | Acknowledgments | 115 |
| | References | 115 |
| 4. | External Factors Affecting Protein Aggregation | 119 |
| | <i>Wei Wang, Ning Li, and Stan Speaker</i> | |
| 4.1 | Introduction | 119 |
| 4.2 | Protein Aggregation Pathways | 120 |
| 4.2.1 | Physical Aggregation through Formation of Unfolding Intermediates | 120 |
| 4.2.2 | Direct Aggregation through Self-Association or Chemical Linkages | 127 |
| 4.2.3 | Indirect Aggregation through Chemical Degradation | 129 |
| 4.2.4 | Protein Aggregation from the Unfolded State | 129 |
| 4.2.5 | Aggregation Nucleation | 130 |
| 4.2.6 | Multiplicity in Protein Aggregation | 131 |
| 4.3 | Effects of Temperature | 132 |
| 4.3.1 | Relationship between Temperature and Protein Stability | 132 |
| 4.3.2 | Effect of High Temperature on Protein Aggregation | 133 |
| 4.3.3 | Melting Temperature (T_m) and Protein Aggregation | 135 |
| 4.3.4 | Effects of Low Temperature | 136 |
| 4.4 | Effects of Solution Conditions and Composition on Protein Aggregation | 136 |
| 4.4.1 | Solution pH | 137 |
| 4.4.2 | Type and Concentration of Buffering Agents | 140 |
| 4.4.3 | Ionic Strength | 141 |
| 4.4.4 | Excipients/Additives | 143 |
| 4.4.5 | Protein Concentration | 154 |
| 4.4.6 | Metal Ions | 157 |

| | | |
|-----------|--|------------|
| 4.4.7 | Denaturant and Reducing Agents | 159 |
| 4.4.8 | Impurities | 160 |
| 4.4.9 | Organic Solvents | 161 |
| 4.4.10 | Containers/Closures | 162 |
| 4.4.11 | Sources of Proteins | 163 |
| 4.4.12 | Light | 163 |
| 4.5 | Effects of Processing Steps on Protein Aggregation | 164 |
| 4.5.1 | Fermentation/Expression | 164 |
| 4.5.2 | Unfolding/Refolding | 165 |
| 4.5.3 | Purification | 168 |
| 4.5.4 | Freeze-Thaw | 168 |
| 4.5.5 | Agitation | 169 |
| 4.5.6 | High Hydrostatic Pressure | 170 |
| 4.5.7 | Drying | 171 |
| 4.5.8 | Preparation of Protein Delivery Systems | 173 |
| 4.5.9 | Analytical Methodologies | 173 |
| 4.5.10 | Miscellaneous Processes | 173 |
| 4.6 | Effects of Solid-State Condition and Composition on Protein Aggregation | 174 |
| 4.6.1 | Solid-State “pH” | 174 |
| 4.6.2 | Excipients and Excipient Levels | 174 |
| 4.6.3 | Physical State of the Solid | 176 |
| 4.6.4 | Moisture Content | 177 |
| 4.7 | Summary | 177 |
| | Acknowledgment | 178 |
| | References | 178 |
| 5. | Experimental Detection and Characterization of Protein Aggregates | 205 |
| | <i>Vikas K. Sharma and Devendra S. Kalonia</i> | |
| 5.1 | Introduction | 205 |
| 5.2 | Aggregate Classification | 206 |
| 5.2.1 | Aggregate Nomenclature | 209 |
| 5.3 | Analytical Tools for the Characterization of Aggregates | 212 |
| 5.3.1 | SEC | 221 |
| 5.3.2 | Light Scattering | 223 |
| 5.3.3 | Analytical Ultracentrifugation (AUC) | 228 |

| | | |
|-----------|---|------------|
| 5.3.4 | FFF | 231 |
| 5.3.5 | Electrophoresis | 233 |
| 5.3.6 | Turbidimetry and Nephelometry | 235 |
| 5.3.7 | Analytical Techniques for Subvisible Particles | 237 |
| 5.3.8 | Visible Particles | 240 |
| 5.3.9 | Miscellaneous Technologies for Characterization of Protein Aggregates | 241 |
| 5.3.10 | Protein Structural Characterization in Aggregates: Spectroscopy-Based Techniques | 245 |
| 5.4 | Summary | 246 |
| | References | 247 |
| 6. | Approaches to Control Protein Aggregation during Bulk Production | 257 |
| | <i>Linda O. Narhi, Yijia Jiang, Rohini Deshpande, Sohye Kang, and Joseph Shultz</i> | |
| 6.1 | Introduction | 257 |
| 6.2 | Candidate Selection | 257 |
| 6.2.1 | Sequence Analysis | 258 |
| 6.2.2 | Stability to Process Conditions | 259 |
| 6.2.3 | Focus on Stability to Formulation and Long-Term Storage Conditions | 265 |
| 6.2.4 | Specific Considerations for Mammalian Cell Culture-Derived Protein | 268 |
| 6.2.5 | Specific Considerations for Bacteria-Derived Protein | 268 |
| 6.3 | Protein Aggregation and Cell Culture | 269 |
| 6.3.1 | Expression Strategies | 269 |
| 6.3.2 | Bioreactor Conditions | 270 |
| 6.4 | Protein Aggregation and Purification | 271 |
| 6.4.1 | Preventing Aggregation with Appropriate Solvent Conditions | 274 |
| 6.4.2 | Removal of Aggregates during Processing | 281 |
| 6.4.3 | Specific Considerations for Mammalian Cell-Derived Protein | 285 |
| 6.4.4 | Specific Considerations for Bacterial-Derived Proteins | 285 |
| 6.4.5 | Bulk DS Stability and Storage | 292 |
| 6.4.6 | Scale-Up | 293 |

| | | |
|-----------|--|------------|
| 6.5 | Summary | 295 |
| | References | 295 |
| 7. | Protein Aggregation and Particle Formation: Effects of Formulation, Interfaces, and Drug Product Manufacturing Operations | 301 |
| | <i>Hanns-Christian Mahler, Stefan Fischer, Theodore W. Randolph, and John F. Carpenter</i> | |
| 7.1 | Introduction | 301 |
| 7.2 | Roles of Conformational and Colloidal Stability in Reducing Rates of Aggregation | 302 |
| 7.2.1 | Conformational Stability | 303 |
| 7.2.2 | Colloidal Stability | 305 |
| 7.3 | Effects of Interfaces on Protein Aggregation | 305 |
| 7.3.1 | Effects of Air–Water Interface | 305 |
| 7.3.2 | Protein Aggregation at Solid–Liquid Interfaces | 306 |
| 7.3.3 | Effects of Excipients on Structural Perturbation and Aggregation at Surfaces | 307 |
| 7.3.4 | Interactions of Proteins with Microparticle Surfaces | 309 |
| 7.3.5 | Protein Aggregation at Silicone Oil/Water Interfaces | 309 |
| 7.3.6 | Shear Effects on Protein Aggregation | 309 |
| 7.4 | Critical Processing Steps during Drug Product Manufacturing of Biopharmaceuticals | 310 |
| 7.4.1 | Freezing and Thawing Operations | 310 |
| 7.4.2 | Mixing of Bulk Drug Solution after Thawing or Pooling | 313 |
| 7.4.3 | Preparation of Final Formulation with Excipients | 313 |
| 7.4.4 | Filtration | 314 |
| 7.4.5 | Filling | 314 |
| 7.5 | Particles in Parenteral Products and Visible Inspection | 316 |
| 7.5.1 | Introduction: Understanding of Particles from the Parenteral Product Viewpoint is Important for Protein Biopharmaceutical Developers | 316 |
| 7.5.2 | The History of Visible Inspection and Particle Contamination Control in Parenteral Products | 316 |

| | | |
|-----------|---|------------|
| 7.5.3 | Current Regulatory Requirements on Particulate Contamination and Control of Subvisible and Visible Particles in Parenteral Products in the EU, United States, and Japan | 317 |
| 7.5.4 | Subvisible Particle Measurements | 317 |
| 7.5.5 | Subvisible Particle Acceptance Criteria | 318 |
| 7.5.6 | Visual Inspection Requirements | 320 |
| 7.5.7 | Visual Inspection Methods | 321 |
| 7.5.8 | What Does “Visible” Mean? | 322 |
| 7.5.9 | Potential Causes of Particulate Contamination in Parenteral Products | 323 |
| 7.6 | Summary and Outlook | 324 |
| | References | 325 |
| 8. | Approaches to Managing Protein Aggregation in Product Development | 333 |
| | <i>Wei Wang and Nicholas W. Warne</i> | |
| 8.1 | Introduction | 333 |
| 8.2 | Approaches in Formulation Development | 334 |
| 8.2.1 | Traditional Formulation Development | 334 |
| 8.2.2 | High-Throughput Formulation Development (HTFD) | 344 |
| 8.2.3 | Computer-Assisted Design of Formulations | 344 |
| 8.3 | Protection of Proteins in Various Processing Steps | 345 |
| 8.3.1 | Shaking | 346 |
| 8.3.2 | Freezing/Thawing | 346 |
| 8.3.3 | Manufacturing Processes for Liquid Drug Product | 347 |
| 8.3.4 | Drying | 348 |
| 8.3.5 | Reconstitution | 350 |
| 8.3.6 | Preparation of Controlled Protein Delivery Systems | 350 |
| 8.3.7 | Miscellaneous Processes | 351 |
| 8.4 | Aggregation Control by Structural Modifications | 351 |
| 8.4.1 | Mutagenesis | 351 |
| 8.4.2 | PEGylation | 352 |
| 8.4.3 | Glycosylation | 353 |

| | | |
|-----------|---|------------|
| 8.5 | Summary | 353 |
| | References | 354 |
| 9. | Case Studies Involving Protein Aggregation | 367 |
| | <i>Rahul S. Rajan, Tiansheng Li, and Tsutomu Arakawa</i> | |
| 9.1 | Introduction | 367 |
| 9.2 | Case Study 1: Aggregation in the Liquid State: The Role of Osmolytes in Stabilizing KGF toward Aggregation | 368 |
| 9.2.1 | Background | 368 |
| 9.2.2. | Model Protein and Conditions | 369 |
| 9.2.3 | Results and Interpretation | 369 |
| 9.2.4 | Discussion and Lessons Learned | 372 |
| 9.3 | Case Study 2: Aggregation in the Liquid State: Heterogeneity and Non-Linearity in IgG2 Aggregation during Long-Term Storage | 376 |
| 9.3.1 | Background | 376 |
| 9.3.2 | Model Protein and Conditions | 378 |
| 9.3.3 | Results and Interpretation | 378 |
| 9.3.4 | Discussion and Lessons Learned | 380 |
| 9.4 | Case Study 3: Aggregation in the Frozen State: The Role of Excipient Crystallization | 381 |
| 9.4.1 | Background | 381 |
| 9.4.2 | Model Protein and Conditions | 382 |
| 9.4.3 | Results and Interpretation | 382 |
| 9.4.4 | Discussion and Lessons Learned | 383 |
| 9.5 | Case Studies 4 and 5: Aggregation in the Lyophilized State: Role of Residual Moisture and Mechanisms of Excipient Stabilization | 385 |
| 9.5.1 | Background | 385 |
| 9.5.2 | Model Protein and Conditions (Case Study 4) | 386 |
| 9.5.3 | Results and Interpretation (Case Study 4) | 387 |
| 9.5.4 | Model Protein and Conditions (Case Study 5) | 388 |
| 9.5.5 | Results and Interpretation (Case Study 5) | 389 |
| 9.5.6 | Discussion and Lessons Learned | 390 |
| 9.6 | Case Study 6: Protein Particulation Due to Nucleation by Foreign Material in Fill/Finish Manufacturing Operations | 391 |
| 9.6.1 | Background | 391 |
| 9.6.2 | Model Protein and Conditions | 391 |

| | | |
|------------|---|------------|
| 9.6.3 | Results and Interpretation | 392 |
| 9.6.4 | Discussion and Lessons Learned | 393 |
| 9.7 | Overall Discussion | 394 |
| 9.7.1 | Are Aggregates Created Equal? | 394 |
| 9.7.2 | Future Directions | 396 |
| | Acknowledgments | 396 |
| | References | 396 |
| 10. | Aggregation and Immunogenicity of Therapeutic Proteins | 403 |
| | <i>Vasco Filipe, Andrea Hawe, Huub Schellekens, and Wim Jiskoot</i> | |
| 10.1 | Introduction | 403 |
| 10.2 | Immunogenicity of Therapeutic Proteins | 404 |
| 10.2.1 | Incidence of Immunogenicity during Therapy | 404 |
| 10.2.2 | Consequences of Protein Immunogenicity for Patients | 405 |
| 10.2.3 | Factors Playing a Role in Protein Immunogenicity | 406 |
| 10.3 | Immune Mechanisms Related to Protein Immunogenicity | 409 |
| 10.3.1 | Immune Responses to Therapeutic Proteins | 410 |
| 10.3.2 | Immune Tolerance | 411 |
| 10.3.3 | B-Cell Activation Mechanisms | 411 |
| 10.3.4 | Breaking of B-Cell Immune Tolerance | 415 |
| 10.4 | Aggregates and Immunogenicity | 415 |
| 10.4.1 | Evidence of Aggregates as a Risk Factor for Immunogenicity | 417 |
| 10.4.2 | Proposed Mechanisms of Antibody Induction by Protein Aggregates | 420 |
| 10.4.3 | Possible Factors Responsible for the Immunogenicity of Protein Aggregates | 423 |
| 10.4.4 | Risk Analysis of Protein Aggregates | 426 |
| 10.4.5 | Predictive Models to Assess the Immunogenicity of Aggregates | 426 |
| 10.5 | Conclusions | 427 |
| | References | 428 |
| 11. | Regulatory Perspective on Aggregates as a Product Quality Attribute | 435 |
| | <i>Wendy C. Weinberg, Linan Ha, Susan L. Kirshner, and Daniela I. Verthelyi</i> | |

- 11.1 Introduction 435
- 11.2 An Overview of the Regulatory Process 436
 - 11.2.1 Drug Development to Licensure 436
 - 11.2.2 Pre- and Post-Marketing Comparability 438
- 11.3 Product Aggregates and Safety Concerns 438
 - 11.3.1 Aggregates and Immunogenicity 438
- 11.4 The Assessment of Aggregates: Regulatory Approaches to Controlling Product Aggregation 440
 - 11.4.1 Factors Contributing to the Formation of Aggregates 440
 - 11.4.2 Selection and Validation of Detection Methods 440
 - 11.4.3 Setting Specifications for Aggregates as Part of Lot Release and Stability Testing 444
 - 11.4.4 Commonly Used Guidance Documents Relating to Control of Aggregates 445
- 11.5 Future Challenges 446
 - 11.5.1 Control of Subvisible Particulates: A Gap in Regulatory Science 446
 - 11.5.2 Assessment of Biosimilars 446
- 11.6 Summary 447
- Acknowledgments 447
- Disclaimer 447
- References 448

Index 453